Recursion Pharmaceuticals Inc (RXRX)
9.29
-0.08
(-0.85%)
USD |
NASDAQ |
Jun 18, 09:32
Recursion Pharmaceuticals Cash from Financing (Quarterly): 13.90M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 13.90M |
| December 31, 2023 | 80.66M |
| September 30, 2023 | 53.76M |
| June 30, 2023 | 3.787M |
| March 31, 2023 | 1.922M |
| December 31, 2022 | 147.26M |
| September 30, 2022 | 2.337M |
| June 30, 2022 | 2.668M |
| March 31, 2022 | 2.084M |
| Date | Value |
|---|---|
| December 31, 2021 | 3.796M |
| September 30, 2021 | -11.10M |
| June 30, 2021 | 463.70M |
| March 31, 2021 | 2.134M |
| December 31, 2020 | 10.04M |
| September 30, 2020 | 229.72M |
| June 30, 2020 | 0.382M |
| March 31, 2020 | 5.997M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-11.10M
Minimum
Sep 2021
463.70M
Maximum
Jun 2021
59.59M
Average
3.796M
Median
Dec 2021
Cash from Financing (Quarterly) Benchmarks
| Eli Lilly and Co | -311.30M |
| Viking Therapeutics Inc | 606.04M |
| Actinium Pharmaceuticals Inc | 14.77M |
| Macrogenics Inc | 0.248M |
| Marinus Pharmaceuticals Inc | 0.257M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -102.30M |
| Cash from Investing (Quarterly) | -6.653M |
| Free Cash Flow | -330.63M |
| Free Cash Flow Per Share (Quarterly) | -0.4616 |
| Free Cash Flow to Equity (Quarterly) | -108.94M |
| Free Cash Flow to Firm (Quarterly) | -108.95M |
| Free Cash Flow Yield | -16.29% |